Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) and OmniAb (NASDAQ:OABI – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Institutional and Insider Ownership
78.5% of Data Knights Acquisition shares are owned by institutional investors. Comparatively, 42.3% of OmniAb shares are owned by institutional investors. 23.1% of Data Knights Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Data Knights Acquisition has a beta of 0.02, meaning that its stock price is 98% less volatile than the S&P 500. Comparatively, OmniAb has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Data Knights Acquisition | N/A | -4.45% | 0.35% |
| OmniAb | N/A | -1.51% | -0.40% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Data Knights Acquisition and OmniAb, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Data Knights Acquisition | 0 | 0 | 0 | 0 | N/A |
| OmniAb | 0 | 0 | 9 | 0 | 3.00 |
OmniAb has a consensus target price of $10.00, suggesting a potential upside of 191.55%. Given OmniAb’s higher probable upside, analysts clearly believe OmniAb is more favorable than Data Knights Acquisition.
Earnings and Valuation
This table compares Data Knights Acquisition and OmniAb’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Data Knights Acquisition | N/A | N/A | $340,000.00 | $0.03 | 359.00 |
| OmniAb | $59.08 million | 6.71 | -$22.33 million | N/A | N/A |
Data Knights Acquisition has higher earnings, but lower revenue than OmniAb.
Summary
Data Knights Acquisition beats OmniAb on 5 of the 9 factors compared between the two stocks.
About Data Knights Acquisition
Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
About OmniAb
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for Data Knights Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Data Knights Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
